Page 48 Opióides

Bibliografia

1. Corbett A, McKnight S, Henderson G. Opioid Receptors. www.opioids.com.
2. Dhawan BN, et al. International Union of Pharmacology. XIII. Classification of Opioid Receptors.
Pharmacol Ver 1996;48:567-92.
3. Cox BM. “Opioid Receptors” in: The IUPHAR Compendium of Receptor Characterization and Clas-
sification, 2nd edition. IUPHAR Media, Londres, Reino Unido 2000;321-36.
4. McQuay. Opioids in Chronic Pain. Br J Anaesth 1989;63:213-6.
5. Inturrisi CE. Clinical Pharmacology of Opioid Analgesics. Anesth Clin of North Am 1989;7(1):
33-49.
6. Duthie DJR, Nimmo WS. Adverse Effects of Opioid Analgesic Drugs. Br J Anaesth 1987;59:61-77.
7. Tavares JC. Farmacologia dos opiáceos. Cadernos de Anestesia e Terapêutica da Dor – Opióides, Ed.
Lucindo Ormonde CAR:9-25.
8. Budd K. Recent advances in the treatment of chronic pain. Br J Anaesth 1989;63:207-12.
9. Lugo RA, Kern SE. Clinical pharmacokinetics of morphine. J Pain Palliat Care Pharmacother
2002;16(4):5-18.
10. Conno FD, Ripamonti C, Sbanotto A, et al. The pharmacological management of cancer pain. Annals
of Oncology 1993;4:267-76.
11. Donnelly S, Davis MP, Walsh D, Naughton M. Morphine in cancer pain management: a practical guide.
Support Care Cancer 2002;10(1):13-35.
12. Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their deriva-
tives: theory and clinical reality, part I. Psychosomatics 2003;44(2):167-71.
13. Kofke WA, Firestone LL. Table A-1. Commonly Used Drugs in Clinical Anesthesia Procedures of the
Massachussets General Hospital. Little, Brown and Company, Boston/Toronto, 1988. Sorkin LS. Pain
Pathways and Spinal Modulation. Anesth Clin of North Am 1989;7(1):17-31.
14. Andersen G, Christrup L, Sjogren P. Relationships among morphine metabolism, pain and side effects
during long-term treatment: an update. J Pain Symptom Manage 2003;25(1):74-91.
15. Sorkin LS. Pain Pathways and Spinal Modulation. Anesth Clin of North Am 1989;7(1):17-31.
16. Mitchell RWD, Smith G. The Control of Acute Postoperative Pain. Br J Anaesth 1989;63:147-58.
17. Donnelly S, Davis MP, Walsh D, Naughton M. Morphine in cancer pain management: a practical guide.
Support Care Cancer 2002 Jan;10(1):13-35.
18. Inturrisi CE. Management of cancer pain. Cancer 1989;63:2308-20.
19. Inturrisi CE, Colburn WA. Pharmacokinetics of methadone. Em: Foley KM, Inturrisi CE, eds. Opioid
Analgesics In the Management of Clinical Pain: Advances in Pain Research and Therapy, vol 8. New
York: Raven Press 1986;191-9.
20. Ettinger DS, Vitale PJ, Trump DL. Important clinical pharmacology considerations in the use of
methadone in cancer patients. Cancer Treat Rep 1979;63:457-59.
21. Duthie DJR. Remifentanil and tramadol. Br J Anaesth 1998;81:51-7.
22. Budd K, Langford R. Tramadol revisited. Br J Anaesth 1999;82:493-5.
23. Jacox A, Carr DB, Payne R, et al. Clinical Practice Guideline: Management of Cancer Pain. Rockville,
MD: US Dept of Health and Human Serbvices 1994:39-74.
24. Physicians Desk Reference. Montvalel NJ. Medical Economics Co 1998.
25. Furuyama Y, Yamamuro M. Strong opioids. Nippon Rinsho 2001 Sep;59(9):1783-8.
26. Kaiko RF, Foley KM, Grabinsky PY, et al. Central nervous system excitatory effects of meperidine in
cancer patients. Ann Neurol 1983;13:180-5.
27. Portenoy RK. Continuous intravenous infusions of opioid drugs. Med Clin North Am 1987;71:233-41.
28. Kerr IG, Sone M, DeAngelis C, et al. Continuous narcotic infusion with patient-controlled analgesia
for chronic cancer pain in outpatients. Ann Intern Med 1988;108:554-7.
29. Baumann TJ, Batenhorst RL, Graves DA, et al. Patient controlled analgesia in the terminally ill cancer
patient. Drug Intell Clin Pharm 1986;20:297-301.

45